Sublingual Immunotherapy vs Allergy Shots Total Cost Over Three Years

Telehealth allergy care with sublingual immunotherapy drops can generally be paid for with FSA or HSA funds, even when insurance does not cover the drops. Over three years, self-pay drops can cost about the same as, or less than, insured allergy shots once copays, travel, and time away from work are included.

Why comparing immunotherapy costs requires looking beyond the insurance card

“Shots are covered, drops are not” sounds like enough information to make a financial decision. It leaves the patient’s share largely unexplored. Both subcutaneous immunotherapy, or SCIT, and sublingual immunotherapy, or SLIT, typically involve three to five years of treatment, so even small recurring expenses can accumulate into thousands of dollars. AAOA Patient Resources warns that coverage language can leave patients “lulled into a false sense of security” about what they will pay. What does insurance actually absorb, and what remains the patient’s responsibility over a course of treatment?

How allergy shots are priced and what "covered by insurance" actually means in practice

Allergy shots have two phases, each with a different visit burden. During build-up, patients usually get injections weekly or twice weekly for three to six months. Maintenance then involves injections every two to four weeks for the remaining years. That change affects the cost. A quote based on a maintenance visit alone will not describe the more frequent appointments at the start, while a calculation assuming weekly visits throughout may overstate the usual maintenance burden.

AAOA notes that copays may apply per shot and that most allergists divide treatment into two serums, which can mean a higher payment per session than the patient expected. The distinction is easy to miss. A patient asking only whether immunotherapy is covered may not learn whether one visit involves one copay or two. The appointment is a single event on the calendar, but the billing may not treat it that way.

Insurance terms also vary by plan and state, including between plans available through the same employer. There is no single insured price for shots. The relevant baseline is the patient’s own copay structure applied to the proposed build-up and maintenance schedule. To establish that baseline before treatment, patients should get coverage terms in writing, including how the plan handles vials and two-serum protocols. Otherwise, “covered” remains an incomplete description of the financial commitment.

The costs that don't appear on an Explanation of Benefits: time, travel, and monitoring visits

Consider a patient trying to fit a shot into a lunch break. The injection itself is only part of the appointment, because the trip, clinic wait, and required post-injection observation period also take time. If that block runs beyond the break, the choice may become using PTO or losing paid work. Neither expense appears on an insurer’s benefits statement. Yet both belong in a comparison with treatment taken at home.

The same appointment has a different financial weight for different households. Someone who lives close to the clinic and has a flexible schedule may absorb it easily, while someone with a longer trip or caregiving obligations may struggle to attend. Transportation adds another recurring expense. Across repeated visits, these demands can amount to days of lost productivity, even when the medical copay looks manageable. AAOA’s discussion of hidden costs deals with copays, but travel and time add another layer of costs for the patient.

That layer can also change whether treatment gets completed. A clinic schedule that repeatedly conflicts with work or care responsibilities can lead to missed doses and eventual discontinuation. This is more than an inconvenience. A patient who pays for part of a course may still miss out on the lasting benefit they hoped for. The burden of attendance therefore belongs in both the cost estimate and the judgment about which treatment is practical.

Can I use FSA or HSA funds for sublingual immunotherapy through telehealth?

HSA and FSA funds can generally be applied to allergy drop treatment, including treatment arranged through telehealth. That gives eligible patients a way to use pre-tax dollars when insurance does not pay for the drops. It is not insurance coverage, however. Eligibility for account funds and acceptance of a particular payment method are also distinct questions, so this general rule does not establish the payment policy of any individual service.

Custom drops are typically self-pay, in part because they are an off-label treatment in the domestic market. Insurance coverage works differently for FDA-approved SLIT tablets, which some plans may cover. The ACAAI identifies approved tablets for ragweed, northern pasture grasses like timothy, and dust mites. Those distinctions affect the comparison. Without insurance, tablet prices can sit at the higher end of the SLIT range, so a quote for custom drops should not stand in for a tablet prescription.

For drops, the recurring treatment expense is simpler than a series of administered injections. Daily dosing at home avoids repeated administration fees, travel, and post-injection waiting periods. Telehealth can also offer a virtual consultation, at-home finger-prick testing, and drops delivered to the home, so those steps need no trips to the clinic. Testing still belongs in the ledger. A full quote needs the medication price for the year as well as the monthly price and any testing charges, and it must show any required initial supervision apart from routine home dosing.

The side-by-side three-year total for an insured shot patient versus a self-pay SLIT patient

AAOA puts three years of shot copays at $3,120 to $6,240 in its example, depending on whether treatment uses one or two serums. That example assumes weekly visits throughout the three years. It is not a universal total. Because maintenance commonly shifts to every two to four weeks, the figure should not be applied unchanged to every proposed treatment schedule. Its value is to show how substantial covered treatment can become before indirect expenses enter the calculation.

For the insured shot patient, the direct-cost line includes the copays and other out-of-pocket charges required by the plan. The indirect-cost line adds the cost of travel and the value of the time spent getting to appointments, waiting, and being seen. The three-year total adds those two lines for both build-up and maintenance. For the self-pay drop patient, the direct-cost line uses the quoted medication price over the same period, plus testing and any other quoted charges. With routine home dosing, patients avoid the cost of repeated clinic trips and checks after injections, and using FSA or HSA funds may lower what they pay after tax.

To work out which costs less, a patient needs an actual SLIT quote. No single drop price can fill that gap for every patient, and the shot copay example alone does not establish a universal saving. Shots may cost less in cash when the clinic is nearby, copays are low, and work hours are flexible. Higher copays, longer trips, or lost pay can bring the totals closer together or make drops cost less.

Efficacy and safety trade-offs that belong in the same conversation as cost

Shots have an efficacy edge that deserves consideration, especially for a patient who can reliably attend treatment. AAOA describes SLIT as 90% as effective for most allergens, but that comparison is not a promise about an individual patient’s response. Cost cannot settle clinical suitability by itself. A less expensive course is not necessarily better value if it is poorly matched to the patient’s treatment needs.

Duration of benefit adds another important distinction. Post-treatment benefit from SCIT is documented at seven to twelve or more years, while SLIT generally has shorter follow-up data in the two-to-four year range. That is a strong reason why shots may be worth their cost over time for patients who finish the course. It does not prove that SLIT benefit ends when its follow-up data end. A three-year spending comparison therefore captures the treatment window more clearly than it captures all the years of possible benefit afterward.

SLIT has a meaningfully lower risk of systemic reactions, allowing home dosing after the first dose under physician supervision, while shots require observation after every injection. Completion remains crucial for either approach. An efficacy advantage under clinical conditions does not automatically outweigh a home regimen that a particular patient is more likely to finish, although daily drops still require sustained adherence.

The cost of doing nothing, or of staying on symptom-masking medications indefinitely

If neither course is completed, the alternative is often ongoing spending on symptom management. Antihistamines and nasal sprays can provide relief, but they do not change the underlying immune response as immunotherapy aims to do. Their cost can therefore recur indefinitely. A comparison limited to shots versus drops misses this third ledger, including medication purchases and the consequences of symptoms that remain uncontrolled.

Symptom relief also has limits and trade-offs. Antihistamines help sneezing, itching, and a runny nose but have limited effects on nasal congestion. First-generation antihistamines can cause sedation, impaired concentration, and memory effects that reduce productivity at work. Nasal sprays can ease symptoms without offering the same prospect of lasting immune change. Those limits change what repeated spending on symptom medicines buys.

Uncontrolled allergic inflammation can contribute to chronic sinusitis, asthma exacerbations, secondary infections, and disrupted sleep. Nasal obstruction can also lead to mouth breathing, which may worsen sleep and compound fatigue and brain fog. When they occur, their medical bills, missed workdays, and effects on daily life add to the cost of undertreated allergies. Immunotherapy can therefore be economically reasonable even when its upfront price exceeds the immediate cost of symptom medicines, though that judgment depends on benefit and completion and savings remain uncertain.

How to build your own three-year cost estimate before choosing a treatment path

To turn this comparison into a decision, start with written information from the insurance plan. Ask what shot coverage includes, how many vials it covers, what copay applies, and whether two-serum treatment means one copay or two. Then use those terms to work out the cost of the clinic’s proposed schedule. Count the visits for build-up and maintenance on their own. Using the actual schedule keeps a weekly-shot example from standing in for a course with fewer maintenance appointments.

Next, estimate the round-trip transportation expense and the time required for each visit, including waiting and observation. Assign that time a dollar value based on an honest assessment of what attendance costs you. Keep lost pay distinct from lost flexibility. PTO or a flexible schedule may prevent a wage deduction without making the time commitment disappear, and that distinction helps keep the cash comparison clear.

For the SLIT side, get a concrete quote from a local allergist or telehealth provider. Compare what the medication costs for a year, add testing fees and any required initial supervision, and leave out the repeated fees for giving injections and trips to the clinic when counting the cost of home dosing. Then factor in available FSA or HSA funds. Where pre-tax funds cover treatment, the effective cost is lower than the sticker price according to the applicable marginal tax rate. A predictable monthly price becomes useful only after these other terms are clear.

If the totals land close together, the remaining question is practical. Which regimen can fit into daily life for the full course? Telehealth consultation, at-home testing, and delivered drops can show patients how home treatment would work before they commit, while the shot schedule shows how often they would need to attend. For patients whose work or care obligations make clinic visits difficult, that difference can decide whether treatment is sustainable.